Werewolf Therapeutics, Inc. (HOWL) stock
Close on Nov 20, 2026Market cap $46.00MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $46.00M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.82
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$34.61M
- EPS, diluted
- -$0.72
- Free cash flow
- -$60.29M
- Book value per share
- $0.34
- Diluted shares
- 49M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $0.99
- Open
- $0.95
- Day's range
- $0.93 – $0.99
- Volume
- 374,029
- Average volume (20 days)
- 453,367
- Beta (5 years)
- 1.09
- 52-week range
- $0.27 – $1.20
- RSI (14 days)
- 43.4
- Volatility (1 year)
- 141.7%
- Relative volume
- 0.08×
- WACC
- 10.5%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 20, 2026. The S&P 500 is measured by the SPY fund.
| Period | HOWL | S&P 500 | Difference | HOWL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.8% | -10.3% | +0.5 pts | ||
| 3 months | +119.5% | -9.3% | +128.8 pts | ||
| Year to date | +49.4% | +1.9% | +47.5 pts | ||
| 1 year | +10.8% | +6.9% | +3.9 pts | ||
| 3 years | -61.7% | +57.5% | −119.1 pts | -27.4% | +16.3% |
| 5 years | -94.1% | +57.3% | −151.4 pts | -43.2% | +9.5% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Werewolf Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Results
- Results
About Werewolf Therapeutics
Pharmaceutical Preparations
Werewolf Therapeutics is a clinical-stage biopharmaceutical company that designs and develops conditionally activated therapeutics to stimulate the immune system for treating cancer and other immune-mediated conditions. Using its proprietary PREDATOR platform, the company engineers molecules known as INDUKINE and INDUCER therapies, which function as inactive prodrugs systemically and activate selectively within the tumor microenvironment. Its lead product candidates include WTX-124, a conditionally activated Interleukin-2 therapy being evaluated in clinical trials for solid tumors, and WTX-330, an Interleukin-12 molecule being evaluated in clinical studies for advanced or metastatic solid tumors or lymphoma. The company also advances preclinical candidates and partners programs, including licensing rights for JZP898 to Jazz Pharmaceuticals Ireland Limited.
Company profile, executives and historyWerewolf Therapeutics stock: common questions
What is Werewolf Therapeutics's stock price?
HOWL closed at $0.95 on Nov 20, 2026, down 3.97% on the day. Over the past 52 weeks it traded between $0.27 and $1.20.
What is Werewolf Therapeutics's market cap?
Werewolf Therapeutics was worth $46.00M at the close on Nov 20, 2026: the share price times the diluted shares outstanding.
What is HOWL's P/E ratio?
Werewolf Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.72), so it has no meaningful P/E ratio.
Does Werewolf Therapeutics pay a dividend?
No. Werewolf Therapeutics has not paid a cash dividend over the last twelve months.
When does Werewolf Therapeutics report earnings next?
Werewolf Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has HOWL stock performed over the past year?
Including dividends, HOWL returned +10.8% over the past year, against +6.9% for the S&P 500.
How many HOWL shares are sold short?
2M shares were sold short at the latest FINRA report, 5.81% of the float, or 6.4 days of average trading volume.
Who are Werewolf Therapeutics's competitors?
Companies most similar to Werewolf Therapeutics by business, industry and size include NKTR, CTMX, CRVS, PRLD, PLRX.
See a number that looks wrong?